Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.

Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, Savani BN, Storek J, Sullivan KM, Georges GE.

Biol Blood Marrow Transplant. 2019 May;25(5):845-854. doi: 10.1016/j.bbmt.2019.02.014. Epub 2019 Feb 19. Review.

2.

Consider Allogeneic Bone Marrow Transplantation for Older, FitPatients with Aplastic Anemia.

Georges GE.

Biol Blood Marrow Transplant. 2019 Mar;25(3):e69-e70. doi: 10.1016/j.bbmt.2019.01.015. Epub 2019 Jan 11. No abstract available.

PMID:
30641134
3.

Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment.

Georges GE, Doney K, Storb R.

Blood Adv. 2018 Aug 14;2(15):2020-2028. doi: 10.1182/bloodadvances.2018021162. Review.

4.

Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation.

Sullivan KM, Majhail NS, Bredeson C, Carpenter PA, Chatterjee S, Crofford LJ, Georges GE, Nash RA, Pasquini MC, Sarantopoulos S, Storek J, Savani B, St Clair EW.

Biol Blood Marrow Transplant. 2018 Oct;24(10):1961-1964. doi: 10.1016/j.bbmt.2018.06.025. Epub 2018 Jun 25.

PMID:
29953945
5.

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE; SCOT Study Investigators.

N Engl J Med. 2018 Jan 4;378(1):35-47.

6.

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma.

Green DJ, Maloney DG, Storer BE, Sandmaier BM, Holmberg LA, Becker PS, Fang M, Martin PJ, Georges GE, Bouvier ME, Storb R, Mielcarek M.

Blood Adv. 2017 Nov 9;1(24):2247-2256. doi: 10.1182/bloodadvances.2017010686. eCollection 2017 Nov 14.

7.

The Use of Ex Vivo Generated Regulatory T-Cell Preparations in a Canine Lung Allograft Model.

Abrams KV, Hwang B, Nash RA, Georges GE, Lamm W, Storer B, Madtes DK, Glenny R, Mulligan MS.

Transplantation. 2017 Oct;101(10):e326-e327. doi: 10.1097/TP.0000000000001868. No abstract available.

8.

Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.

Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, Freedman MS, Georges GE, Gualandi F, Hamerschlak N, Havrdova E, Kimiskidis VK, Kozak T, Mancardi GL, Massacesi L, Moraes DA, Nash RA, Pavletic S, Ouyang J, Rovira M, Saiz A, Simoes B, Trnený M, Zhu L, Badoglio M, Zhong X, Sormani MP, Saccardi R; Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group.

JAMA Neurol. 2017 Apr 1;74(4):459-469. doi: 10.1001/jamaneurol.2016.5867.

9.

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stuve O, Arnold DL, Wener MH, Georges GE, Wundes A, Kraft GH, Bowen JD.

Neurology. 2017 Feb 28;88(9):842-852. doi: 10.1212/WNL.0000000000003660. Epub 2017 Feb 1.

10.

Hematopoietic stem cell transplantation for acquired aplastic anemia.

Georges GE, Storb R.

Curr Opin Hematol. 2016 Nov;23(6):495-500. Review.

11.

Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia.

Cassaday RD, Alan Potts D Jr, Stevenson PA, Bar M, Georges GE, Shustov AR, Sorror ML, Wood BL, Delaney C, Doney KC, Storb RF, Sandmaier BM.

Leuk Lymphoma. 2016 Sep;57(9):2109-18. doi: 10.3109/10428194.2016.1160080. Epub 2016 Mar 22.

12.

In utero transplantation may soon be in delivery.

Georges GE.

Blood. 2014 Sep 18;124(12):1854-5. No abstract available.

13.

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O, Arnold DL, Spychala ME, McConville KC, Harris KM, Phippard D, Georges GE, Wundes A, Kraft GH, Bowen JD.

JAMA Neurol. 2015 Feb;72(2):159-69. doi: 10.1001/jamaneurol.2014.3780.

14.

Autologous hematopoietic stem cell therapy in severe systemic sclerosis: ready for clinical practice?

Khanna D, Georges GE, Couriel DR.

JAMA. 2014 Jun 25;311(24):2485-7. doi: 10.1001/jama.2014.6369. No abstract available. Erratum in: JAMA. 2014 Nov 5;312(17):1805.

15.

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindeløv L, Franke GN, Laport GG, Yeager AM, Hübel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM.

J Clin Oncol. 2013 Apr 20;31(12):1530-8. doi: 10.1200/JCO.2012.45.0247. Epub 2013 Mar 11.

16.

Long-term tolerance to kidney allografts after induced rejection of donor hematopoietic chimerism in a preclinical canine model.

Graves SS, Mathes DW, Georges GE, Kuhr CS, Chang J, Butts TM, Storb R.

Transplantation. 2012 Sep 27;94(6):562-8.

17.

Pulmonary administration of a water-soluble curcumin complex reduces severity of acute lung injury.

Suresh MV, Wagner MC, Rosania GR, Stringer KA, Min KA, Risler L, Shen DD, Georges GE, Reddy AT, Parkkinen J, Reddy RC.

Am J Respir Cell Mol Biol. 2012 Sep;47(3):280-7. doi: 10.1165/rcmb.2011-0175OC. Epub 2012 Feb 3.

18.

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.

Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, Agura E, Maziarz RT, Langston A, Hari P, Pulsipher MA, Bethge W, Sahebi F, Bruno B, Maris MB, Yeager A, Petersen FB, Vindeløv L, McSweeney PA, Hübel K, Mielcarek M, Georges GE, Niederwieser D, Blume KG, Maloney DG, Storb R.

JAMA. 2011 Nov 2;306(17):1874-83. doi: 10.1001/jama.2011.1558.

19.

Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors.

Leuci V, Mesiano G, Gammaitoni L, Cammarata C, Capellero S, Todorovic M, Jordaney N, Circosta P, Elia A, Lesnikova M, Georges GE, Piacibello W, Fagioli F, Cignetti A, Aglietta M, Sangiolo D.

J Biotechnol. 2011 Dec 10;156(3):218-26. doi: 10.1016/j.jbiotec.2011.09.001. Epub 2011 Sep 10.

PMID:
21933686
20.

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.

Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey A, Flowers ME, Maris MB, Laport GG, Chauncey TR, Lange T, Langston AA, Storer B, Georges GE.

Haematologica. 2011 Aug;96(8):1113-20. doi: 10.3324/haematol.2011.040261. Epub 2011 Apr 20.

21.

Blood-based detection of radiation exposure in humans based on novel phospho-Smc1 ELISA.

Ivey RG, Moore HD, Voytovich UJ, Thienes CP, Lorentzen TD, Pogosova-Agadjanyan EL, Frayo S, Izaguirre VK, Lundberg SJ, Hedin L, Badiozamani KR, Hoofnagle AN, Stirewalt DL, Wang P, Georges GE, Gopal AK, Paulovich AG.

Radiat Res. 2011 Mar;175(3):266-81. doi: 10.1667/RR2402.1. Epub 2010 Dec 20.

22.

Antagonistic and agonistic anti-canine CD28 monoclonal antibodies: tools for allogeneic transplantation.

Graves SS, Stone DM, Loretz C, Peterson LJ, Lesnikova M, Hwang B, Georges GE, Nash R, Storb R.

Transplantation. 2011 Apr 27;91(8):833-40. doi: 10.1097/TP.0b013e31820f07ff. Erratum in: Transplantation. 2012 Nov;94(10):1074.

23.

Identification of radiation-induced expression changes in nonimmortalized human T cells.

Pogosova-Agadjanyan EL, Fan W, Georges GE, Schwartz JL, Kepler CM, Lee H, Suchanek AL, Cronk MR, Brumbaugh A, Engel JH, Yukawa M, Zhao LP, Heimfeld S, Stirewalt DL.

Radiat Res. 2011 Feb;175(2):172-84. Epub 2010 Nov 17.

24.

Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog leukocyte antigen-haploidentical bone marrow transplantation.

Mielcarek M, Storb R, Georges GE, Golubev L, Nikitine A, Hwang B, Nash RA, Torok-Storb B.

Biol Blood Marrow Transplant. 2011 Feb;17(2):214-25. doi: 10.1016/j.bbmt.2010.08.015. Epub 2010 Oct 30.

25.

Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age.

Sangiolo D, Storb R, Deeg HJ, Flowers ME, Martin PJ, Sandmaier BM, Kiem HP, Nash RA, Doney K, Leisenring WM, Georges GE.

Biol Blood Marrow Transplant. 2010 Oct;16(10):1411-8. doi: 10.1016/j.bbmt.2010.04.005. Epub 2010 Apr 18.

26.

Animal models for medical countermeasures to radiation exposure.

Williams JP, Brown SL, Georges GE, Hauer-Jensen M, Hill RP, Huser AK, Kirsch DG, Macvittie TJ, Mason KA, Medhora MM, Moulder JE, Okunieff P, Otterson MF, Robbins ME, Smathers JB, McBride WH.

Radiat Res. 2010 Apr;173(4):557-78. doi: 10.1667/RR1880.1.

27.

A preclinical model of double- versus single-unit unrelated cord blood transplantation.

Georges GE, Lesnikov V, Baran SW, Aragon A, Lesnikova M, Jordan R, Laura Yang YJ, Yunusov MY, Zellmer E, Heimfeld S, Venkataraman GM, Harkey MA, Graves SS, Storb R, Storer BE, Nash RA.

Biol Blood Marrow Transplant. 2010 Aug;16(8):1090-8. doi: 10.1016/j.bbmt.2010.03.010. Epub 2010 Mar 18.

28.

A novel monoclonal antibody specific for canine CD25 (P4A10): selection and evaluation of canine Tregs.

Abrams VK, Hwang B, Lesnikova M, Gass MJ, Wayner E, Castilla-Llorente C, Georges GE, Nash RA.

Vet Immunol Immunopathol. 2010 Jun 15;135(3-4):257-65. doi: 10.1016/j.vetimm.2009.12.006. Epub 2009 Dec 29.

29.

Delaying DLA-haploidentical hematopoietic cell transplantation after total body irradiation.

Ding Y, Rotta M, Graves SS, Storer BE, Peterson LJ, Sale GE, Forough R, Zellmer E, Georges GE, Sandmaier BM, Kuhr CS, Storb R.

Biol Blood Marrow Transplant. 2009 Oct;15(10):1244-50. doi: 10.1016/j.bbmt.2009.06.004. Epub 2009 Aug 3.

30.

Immunomodulatory effects of mixed hematopoietic chimerism: immune tolerance in canine model of lung transplantation.

Nash RA, Yunosov M, Abrams K, Hwang B, Castilla-Llorente C, Chen P, Farivar AS, Georges GE, Hackman RC, Lamm WJ, Lesnikova M, Ochs HD, Randolph-Habecker J, Ziegler SF, Storb R, Storer B, Madtes DK, Glenny R, Mulligan MS.

Am J Transplant. 2009 May;9(5):1037-47. doi: 10.1111/j.1600-6143.2009.02619.x. Erratum in: Am J Transplant. 2009 Jun;9(6):1486.

31.

Adoptive immunotherapy against allogeneic kidney grafts in dogs with stable hematopoietic trichimerism.

Graves SS, Hogan WJ, Kuhr C, Diaconescu R, Harkey M, Sale GE, Stone B, Georges GE, Storb R.

Biol Blood Marrow Transplant. 2008 Nov;14(11):1201-8. doi: 10.1016/j.bbmt.2008.08.005.

32.

Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection.

Sangiolo D, Lesnikova M, Nash RA, Jensen MC, Nikitine A, Kiem HP, Georges GE.

Gene Ther. 2007 Nov;14(21):1549-54. Epub 2007 Sep 6.

PMID:
17805303
33.

Intussusception in canine recipients of hematopoietic cell grafts and surgical correction.

Yunusov MY, Kerbauy F, Abrams K, Zellmer E, Spector M, Kuhr CS, Hwang B, Storer B, Georges GE, Weigler BJ, Storb R, Nash RA.

Comp Med. 2007 Jun;57(3):287-91.

PMID:
17605344
34.

Stable trichimerism after marrow grafting from 2 DLA-identical canine donors and nonmyeloablative conditioning.

Graves SS, Hogan W, Kuhr CS, Diaconescu R, Harkey MA, Georges GE, Sale GE, Zellmer E, Baran SW, Jochum C, Stone B, Storb R.

Blood. 2007 Jul 1;110(1):418-23. Epub 2007 Mar 16. Erratum in: Blood. 2010 Feb 11;115(6):1313. Baran, Szczepan [corrected to Baran, Szczepan W].

35.

Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.

Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE, Greene JE, Linenberger M, Petersdorf E, Sandmaier BM, Scott BL, Sorror M, Stirewalt DL, Stewart FM, Witherspoon RP, Storb R, Appelbaum FR, Deeg HJ.

Biol Blood Marrow Transplant. 2007 Mar;13(3):355-65.

36.

Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.

Georges GE, Maris MB, Maloney DG, Sandmaier BM, Sorror ML, Shizuru JA, Lange T, Agura ED, Bruno B, McSweeney PA, Pulsipher MA, Chauncey TR, Mielcarek M, Storer BE, Storb R.

Biol Blood Marrow Transplant. 2007 Apr;13(4):423-32. Epub 2007 Feb 1.

37.

Partial donor-specific tolerance to delayed skin grafts after rejection of hematopoietic cell graft.

Yunusov MY, Kuhr CS, Georges GE, Hogan WJ, Taranova AG, Lesnikova M, Kim YS, Abrams K, Hwang B, Sale GE, Storer B, Storb R, Nash RA.

Transplantation. 2006 Sep 15;82(5):629-37.

PMID:
16969285
38.

Denileukin diftitox as prophylaxis against graft-versus-host disease in the canine hematopoietic cell transplantation model.

Mielcarek M, Georges GE, Storb R.

Biol Blood Marrow Transplant. 2006 Sep;12(9):899-904.

39.

Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis.

Nash RA, McSweeney PA, Nelson JL, Wener M, Georges GE, Langston AA, Shulman H, Sullivan KM, Lee J, Henstorf G, Storb R, Furst DE.

Arthritis Rheum. 2006 Jun;54(6):1982-6.

40.

Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation.

Giaccone L, McCune JS, Maris MB, Gooley TA, Sandmaier BM, Slattery JT, Cole S, Nash RA, Storb RF, Georges GE.

Blood. 2005 Dec 15;106(13):4381-8. Epub 2005 Sep 6.

41.

Adoptive immunotherapy to increase the level of donor hematopoietic chimerism after nonmyeloablative marrow transplantation for severe canine hereditary hemolytic anemia.

Takatu A, Nash RA, Zaucha JM, Little MT, Georges GE, Sale GE, Zellmer E, Kuhr CS, Lothrop CD Jr, Storb R.

Biol Blood Marrow Transplant. 2003 Nov;9(11):674-82.

42.

Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model.

Neff T, Horn PA, Peterson LJ, Thomasson BM, Thompson J, Williams DA, Schmidt M, Georges GE, von Kalle C, Kiem HP.

J Clin Invest. 2003 Nov;112(10):1581-8.

43.

Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.

Nash RA, Dansey R, Storek J, Georges GE, Bowen JD, Holmberg LA, Kraft GH, Mayes MD, McDonagh KT, Chen CS, Dipersio J, Lemaistre CF, Pavletic S, Sullivan KM, Sunderhaus J, Furst DE, McSweeney PA.

Biol Blood Marrow Transplant. 2003 Sep;9(9):583-91.

44.

Allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C, Chauncey TR, Doney K, Georges GE, Kiem HP, Martin PJ, Petersdorf EW, Radich J, Sanders JE, Sandmaier BM, Warren EH, Witherspoon RP, Storb R, Appelbaum FR.

Blood. 2003 Dec 1;102(12):3912-8. Epub 2003 Aug 14.

45.

IL-2 does not enhance the conversion to complete donor chimerism following nonmyeloablative hematopoietic cell transplantation in dogs.

Georges GE, Storb R, Maciej Zaucha J, Taranova AG, Gooley T, Nash RA.

Bone Marrow Transplant. 2003 Jun;31(11):1027-31.

PMID:
12774055
46.

High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.

Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS, Storek J, Sullivan KM, Al-Omaishi J, Corboy JR, DiPersio J, Georges GE, Gooley TA, Holmberg LA, LeMaistre CF, Ryan K, Openshaw H, Sunderhaus J, Storb R, Zunt J, Kraft GH.

Blood. 2003 Oct 1;102(7):2364-72. Epub 2003 May 22.

47.

Minor histocompatibility antigen-specific cytotoxic T lymphocytes generated with dendritic cells from DLA-identical littermates.

Georges GE, Lesnikova M, Storb R, Yunusov M, Little MT, Nash RA.

Biol Blood Marrow Transplant. 2003 Apr;9(4):234-42.

48.

FLT3 ligand promotes engraftment of allogeneic hematopoietic stem cells without significant graft-versus-host disease.

Yunusov MY, Georges GE, Storb R, Moore P, Hagglund H, Affolter V, Lesnikova M, Gass MJ, Little MT, Loken M, McKenna H, Storer B, Nash RA.

Transplantation. 2003 Apr 15;75(7):933-40.

PMID:
12698076
49.

Adoptive immunotherapy against kidney targets in dog-leukocyte antigen-identical mixed hematopoietic canine chimeras.

Junghanss C, Takatu A, Little MT, Maciej Zaucha J, Zellmer E, Yunusov M, Sale G, Georges GE, Storb R.

Transplantation. 2003 Feb 15;75(3):268-74.

PMID:
12589144
50.

Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.

Georges GE, Storb R.

Int J Hematol. 2003 Jan;77(1):3-14. Review.

PMID:
12568294

Supplemental Content

Loading ...
Support Center